4.1 Article

Addressing the public health burden of respiratory viruses: the Battle against Respiratory Viruses (BRaVe) Initiative

期刊

FUTURE VIROLOGY
卷 8, 期 10, 页码 953-968

出版社

FUTURE MEDICINE LTD
DOI: 10.2217/fvl.13.85

关键词

antivirals; emerging respiratory viruses; influenza virus; pneumonia; public health policies; respiratory syncytial virus; respiratory viral infections; severe acute respiratory infection; vaccines; WHO research agenda

类别

资金

  1. Sanofi Pasteur
  2. Roche
  3. GSK
  4. AIMM Therapeutics
  5. Crucell BV
  6. AVI BioPharma Inc.

向作者/读者索取更多资源

Given the enormous estimated burden of respiratory virus infections worldwide, a substantial number of research priorities exist in order to better understand their epidemiology, pathogenesis, prevention and clinical management across different populations and resource settings. New therapeutics and specific vaccines for noninfluenza respiratory virus infections could provide enormous benefits in reducing the morbidity and mortality associated with these frequent infections and provide the foundation for responding to newly emerging threats. The BRaVe Initiative is a new WHO-led effort to catalyze multidisciplinary research on strategies to prevent and treat medically important respiratory virus infections with the goal of timely integration of scientific advances and technical innovations into public health practice.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.1
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据